Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917).
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1 / Huhn, Gregory D; Wilkin, Aimee; Mussini, Cristina; Spinner, Christoph D; Jezorwski, John; El Ghazi, Mohsine; Van Landuyt, Erika; Lathouwers, Erkki; Brown, Kimberley; Baugh, Bryan. - In: HIV RESEARCH & CLINICAL PRACTICE. - ISSN 2578-7489. - 21:6(2021), pp. 151-167. [10.1080/25787489.2020.1844520]
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1
Mussini, Cristina;
2021
Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917).
| File | Dimensione | Formato | |
|---|---|---|---|
|
Week 96 subgroup analyses of the phase 3 randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
1.64 MB
Formato
Adobe PDF
|
1.64 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
